Pricing Log in Create free account
Friday 6 November 2026 Export TMO’s income statement to Excel — free account

Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

688.80 11.86 +1.75%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Thermo Fisher Scientific Inc. 10-Q filed Oct 31, 2025

Fiscal Q3 2025 · Period ended Sep 27, 2025 · Filed · accepted 9:36 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 1, 2025: 8 added · 3 removed · 24 modified; 6 with only figures updated; 3 moved without change

  1. Modified · Organic Revenue Growth

    During the secondthird quarter of 2025, revenues grew in the pharma and biotech market due to increased demand from , driven by our trusted partner status with customers. Revenues in the academic and government and industrial and applied markets market declined, reflecting some customer hesitancy in a more uncertain environment, which resulted in muted demand for equipment and instruments. Revenues grew in the industrial and applied market due to strong demand for our innovative products serving this market. Revenue to customers in the diagnostics and healthcare market declined as we navigated headwinds in China. During the secondthird quarter of 2025, sales grew in North America and Europe. Sales declined growth was strong in Europe and Asia-Pacific, including despite weak economic activity in China. Contributions to organic revenue during the secondthird quarter of 2025 from were led by the Laboratory Products and Biopharma Services and Life Sciences Solutions segments were partially offset by declines in the Analytical Instruments segment.